Women with polycystic ovary syndrome are sensitive to the TNF-α-lowering effect of glucose-induced hyperinsulinaemia

European Journal of Clinical Investigation

Volumn 36, Issue 12, 2006, Pages 883-889

  Puder, J ^b   Varga, S ^a   Nusbaumer, C P G ^a   Zulewski, H ^a   Bilz, S ^a   Muller B ^a   Keller, U ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b LAUSANNE UNIVERSITY HOSPITAL   (Switzerland)

Author keywords

Inflammation mediators; Insulin; Insulin resistance; Polycystic ovary syndrome

Indexed keywords

GESTAGEN; GLUCOSE; INSULIN; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; GLUCOSE TOLERANCE; HUMAN; HYPERGLYCEMIA; HYPERINSULINEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; MENSTRUAL CYCLE; ORAL GLUCOSE TOLERANCE TEST; OVARY POLYCYSTIC DISEASE; PRIORITY JOURNAL; SENSITIVITY ANALYSIS; WITHDRAWAL BLEEDING;

ADULT; BLOOD GLUCOSE; FEMALE; HUMANS; HYPERINSULINISM; INSULIN; POLYCYSTIC OVARY SYNDROME; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750701794     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2006.01734.x     Document Type: Article

References (45)

1. Hansen TK, Thiel S, Wouters PJ, Christiansen JS, Van den Berghe G. Intensive insulin therapy exerts antiinflammatory effects in critically ill patients and counteracts the adverse effect of low mannose-binding lectin levels. J Clin Endocrinol Metab 2003;88 (3):1082-8.
2. Van den Berghe G, Wouters PJ, Weekers F, Verwaest C, Bruyninckx F, Schetz M et al. Intensive insulin therapy in the critically ill patients. N Engl J Med 2001;345 (19):1359-67.
3. Stentz FB, Umpierrez GE, Cuervo R, Kitabchi AE. Pro-inflammatory cytokines, markers of cardiovascular risks, oxidative stress, and lipid peroxidation in patients with hyperglycemic crises. Diabetes 2004;53 (8):2079-86.
4. Takebayashi K, Aso Y, Inukai T. Initiation of insulin therapy reduces serum concentrations of high-sensitivity C-reactive protein in patients with type 2 diabetes. Metabolism 2004;53 (6):693-9.
5. Malmberg K. Prospective randomised study of intensive insulin treatment on long-term survival after acute myocardial infarction in patients with diabetes mellitus: DIGAMI (Diabetes Mellitus, Insulin Glucose Infusion in Acute Myocardial Infarction) Study Group. BMJ 1997;314 (7093):1512-5.
6. Yudkin JS, Panahloo A, Stehouwer C, Emeis JJ, Bulmer K, Mohamed-Ali V et al. The influence of improved glycaemic control with insulin and sulphonylureas on acute phase and endothelial markers in Type II diabetic subjects. Diabetologia 2000;43 (9):1099-106.
7. Hotamisligil GS. Inflammatory pathways and insulin action. Int J Obes Relat Metab Disord 2003;27 (Suppl. 3):S53-5.
8. Libby P, Ridker PM, Maseri A. Inflammation and atherosclerosis. Circulation 2002;105 (9):1135-43.
9. Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N Engl J Med 2002;347 (20):1557-65.
10. Blum CA, Muller B, Huber P, Kraenzlin M, Schindler C, De Geyter C et al. Low-grade inflammation and estimates of insulin resistance during the menstrual cycle in lean and over-weight women. J Clin Endocrinol Metab 2005;90 (6):3230-5.
11. Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90 (11):6014-21.
12. Gonzalez F, Thusu K, Abdel-Rahman E, Prabhala A, Tomani M, Dandona P. Elevated serum levels of tumor necrosis factor alpha in normal-weight women with polycystic ovary syndrome 2. Metabolism 1999;48 (4):437-41.
13. Kelly CC, Lyall H, Petrie JR, Gould GW, Connell JM, Sattar N. Low-grade chronic inflammation in women with polycystic ovarian syndrome. J Clin Endocrinol Metab 2001;86 (6):2453-5.
14. Gonzalez F, Rote NS, Minium J, Kirwan JP. Increased activation of nuclear factor kappa B triggers inflammation and insulin resistance in polycystic ovary syndrome. J Clin Endocrinol Metab 2006;91 (4):1508-12.
15. Holte J, Bergh T, Berne C, Lithell H. Serum lipoprotein lipid profile in women with the polycystic ovary syndrome: relation to anthropometric, endocrine and metabolic variables. Clin Endocrinol (Oxf) 1994;41 (4):463-71.
16. Tripathy D, Mohanty P, Dhindsa S, Syed T, Ghanim H, Aljada A et al. Elevation of free fatty acids induces inflammation and impairs vascular reactivity in healthy subjects. Diabetes 2003;52 (12):2882-7.
17. Baillargeon JP, Nestler JE. Commentary: polycystic ovary syndrome: a syndrome of ovarian hypersensitivity to insulin? J Clin Endocrinol Metab 2006;91 (1):22-4.
18. Book CB, Dunaif A. Selective insulin resistance in the polycystic ovary syndrome. J Clin Endocrinol Metab 1999;84(9):3110-6.
19. Nestler JE, Jakubowicz DJ. Decreases in ovarian cytochrome P450c17 alpha activity and serum free testosterone after reduction of insulin secretion in polycystic ovary syndrome. N Engl J Med 1996;335 (9):617-23.
20. Poretsky L. On the paradox of insulin-induced hyperandrogenism in insulin-resistant states. Endocr Rev 1991;12 (1):3-13.
21. Hundal RS, Petersen KF, Mayerson AB, Randhawa PS, Inzucchi S, Shoelson SE et al. Mechanism by which high-dose aspirin improves glucose metabolism in type 2 diabetes. J Clin Invest 2002;109 (10):1321-6.
22. Ridker PM, Cannon CP, Morrow D, Rifai N, Rose LM, McCabe CH et al. C-reactive protein levels and outcomes after statin therapy. N Engl J Med 2005;352 (1):20-8.
23. Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M et al. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 2002;106 (16):2067-72.
24. Dandona P, Aljada A, Chaudhuri A, Bandyopadhyay A. The potential influence of inflammation and insulin resistance on the pathogenesis and treatment of atherosclerosis-related complications in type 2 diabetes. J Clin Endocrinol Metab 2003;88 (6):2422-9.
25. Dandona P, Mohanty P, Chaudhuri A, Garg R, Aljada A. Insulin infusion in acute illness. J Clin Invest 2005;115 (8):2069-72.
26. Van den Berghe G. How does blood glucose control with insulin save lives in intensive care? J Clin Invest 2004;114 (9):1187-95.
27. Nappo F, Esposito K, Cioffi M, Giugliano G, Molinari AM, Paolisso G et al. Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: role of fat and carbohydrate meals. J Am Coll Cardiol 2002;39 (7):1145-50.
28. Manning PJ, Sutherland WH, Hendry G, de Jong SA, McGrath M, Williams SM. Changes in circulating postprandial pro-inflammatory cytokine concentrations in diet-controlled type 2 diabetes and the effect of ingested fat. Diabetes Care 2004;27 (10):2509-11.
29. Wu CJ, Yu ZR. Effects on blood glucose, insulin, lipid and pro-atherosclerotic parameters in stable type 2 diabetic subjects during an oral fat challenge. Lipids Health Dis 2004;3:17.
30. Rotterdam ESHRE/ASRM - Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril 2004;81 (1):19-25.
31. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2005;28 (Suppl. 1):S37-42.
32. Krueger JM, Fang J, Taishi P, Chen Z, Kushikata T, Gardi J. Sleep: A physiologic role for IL-1 beta and TNF-alpha. Ann N Y Acad Sci 1998;856:148-59.
33. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC. Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985;28 (7):412-9.
34. Matsuda M, Defronzo RA. Insulin sensitivity indices obtained from oral glucose tolerance testing: comparison with the euglycemic insulin clamp. Diabetes Care 1999;22 (9):1462-70.
35. Hatch R, Rosenfield RL, Kim MH, Tredway D. Hirsutism: implications, etiology, and management. Am J Obstet Gynecol 1981;140 (7):815-30.
36. Morohoshi M, Fujisawa K, Uchimura I, Numano F. Glucose-dependent interleukin-6 and tumor necrosis factor production by human peripheral blood monocytes in vitro. Diabetes 1996;45 (7):954-9.
37. Schiekofer S, Andrassy M, Chen J, Rudofsky G, Schneider J, Wendt T et al. Acute hyperglycaemia causes intracellular formation of CML and activation of ras, p42/44 MAPK, and nuclear factor kappaB in PBMCs. Diabetes 2003;52 (3):621-33.
38. Hattori Y, Hattori S, Sato N, Kasai K. High-glucose-induced nuclear factor kappaB activation in vascular smooth muscle cells. Cardiovasc Res 2000;46 (1):188-97.
39. Dandona P, Aljada A, Mohanty P, Ghanim H, Hamouda W, Assian E et al. Insulin inhibits intranuclear nuclear factor kappaB and stimulates IkappaB in mononuclear cells in obese subjects: evidence for an anti-inflammatory effect? J Clin Endocrinol Metab 2001;86 (7):3257-65.
40. Gonzalez F, Minium J, Rote NS, Kirwan JP. Hyperglycemia alters tumor necrosis factor-alpha release from mononuclear cells in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2005;90 (9):5336-42.
41. Weisberg SP, McCann D, Desai M, Rosenbaum M, Leibel RL, Ferrante AW Jr. Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 2003;112 (12):1796-808.
42. Xu H, Barnes GT, Yang Q, Tan G, Yang D et al. Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 2003;112 (12):1821-30.
43. Fain JN, Madan AK, Hiler ML, Cheema P, Bahouth SW. Comparison of the release of adipokines by adipose tissue, adipose tissue matrix, and adipocytes from visceral and subcutaneous abdominal adipose tissues of obese humans. Endocrinology 2004;145 (5):2273-82.
44. Kirwan JP, Krishnan RK, Weaver JA, Del Aguila LF, Evans WJ. Human ageing is associated with altered TNF-alpha production during hyperglycemia and hyperinsulinemia. Am J Physiol Endocrinol Metab 2001;281 (6):E1137-43.
45. Carpentier A, Patterson BW, Leung N, Lewis GF. Sensitivity to acute insulin-mediated suppression of plasma free fatty acids is not a determinant of fasting VLDL triglyceride secretion in healthy humans. Diabetes 2002;51 (6):1867-75.